Taken together, our data suggest that reduction in Nurr1‐expressing glutamatergic neurons in the hippocampal formation may be associated with AD, and that Nurr1 activation could be a promising therapeutic strategy to treat AD. This evidence concerns the gene NR4A2 and Alzheimer disease.